



News Release

Suven's Clinical Candidate SUVN-502 Secures European product patent

Hyderabad, India May 5, 2008 – Suven Life Sciences Ltd (Suven) announces today that the European Patent Office (EPO) granted the Product Patent, EP 1581492 to its clinical candidate SUVN-502 which is valid until June 2023. EP 1581492 is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts.

"We are very pleased by the grant of this patent for our clinical candidate SUVN-502 which is being developed for CNS disorders in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's disease (AD), Attention Deficit Hyperactivity Disorder (ADHD), memory impairment associated with aging and Schizophrenia etc, the unmet medical needs. Potential market opportunity for these indications is more than \$18 billion globally. Granting of this patent to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is entering into clinical trials. Securing patent protection for our discoveries enhanced the value of our technologies and products substantially" says Venkat Jasti CEO of Suven Life Sciences.

With EP 1581492, Suven has four European Product Patents granted and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.

In addition to this Suven has obtained product patents from USA (4), India (4), Australia (2), Eurasia (2), Korea (2), Mexico (2), New Zealand (2), and Singapore (2).

The granted claims of all the above patents include the class of selective 5-HT compounds discovered by Suven and are being developed for the treatment of debilitating Central nervous system (CNS) disorders such as Alzheimer's disease, ADHD, depression, Huntington's disease, MCI, memory impairments associated with aging, Parkinson's disease, Schizophrenia, vascular dementia and obesity.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;